Smith MR - Search Results

1

An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.

Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S, Haber DA. Miyamoto DT, et al. Among authors: smith mr. Cancer Discov. 2018 Mar;8(3):288-303. doi: 10.1158/2159-8290.CD-16-1406. Epub 2018 Jan 4. Cancer Discov. 2018. PMID: 29301747 Free PMC article. Clinical Trial.

2

Changes in body composition during androgen deprivation therapy for prostate cancer.

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Smith MR, et al. J Clin Endocrinol Metab. 2002 Feb;87(2):599-603. doi: 10.1210/jcem.87.2.8299. J Clin Endocrinol Metab. 2002. PMID: 11836291 Clinical Trial.

3

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.

Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Smith MR, et al. Cancer. 2002 Nov 1;95(9):1864-8. doi: 10.1002/cncr.10844. Cancer. 2002. PMID: 12404279 Free article. Clinical Trial.

4

Changes in body composition during hormonal therapy for prostate cancer.

Smith MR. Smith MR. Clin Prostate Cancer. 2003 Jun;2(1):18-21. doi: 10.3816/cgc.2003.n.008. Clin Prostate Cancer. 2003. PMID: 15046678 Review.

5

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.

Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Smith MR, et al. J Clin Oncol. 2004 Jul 1;22(13):2546-53. doi: 10.1200/JCO.2004.01.174. J Clin Oncol. 2004. PMID: 15226323 Clinical Trial.

6

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.

Lee H, McGovern K, Finkelstein JS, Smith MR. Lee H, et al. Among authors: smith mr. Cancer. 2005 Oct 15;104(8):1633-7. doi: 10.1002/cncr.21381. Cancer. 2005. PMID: 16116596 Free article. Clinical Trial.

7

Markers of bone metabolism in prostate cancer.

Smith MR. Smith MR. Cancer Treat Rev. 2006;32 Suppl 1:23-6. doi: 10.1016/s0305-7372(06)80006-x. Cancer Treat Rev. 2006. PMID: 16680835 Review.

8

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.

Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Michaelson MD, et al. Among authors: smith mr. Cancer. 2006 Aug 1;107(3):530-5. doi: 10.1002/cncr.22043. Cancer. 2006. PMID: 16804927 Free article. Clinical Trial.

9

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Michaelson MD, et al. Among authors: smith mr. J Clin Oncol. 2007 Mar 20;25(9):1038-42. doi: 10.1200/JCO.2006.07.3361. J Clin Oncol. 2007. PMID: 17369566 Free PMC article. Clinical Trial.

10

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Bell DW, et al. Among authors: smith mr. Int J Cancer. 2007 Dec 15;121(12):2661-7. doi: 10.1002/ijc.23026. Int J Cancer. 2007. PMID: 17721994 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,177 results

Search Page

Filters